Top Page
Smith & Nephew Snats
(NYSE:SNN)
Smith & Nephew Snats (SNN) vs. SPDR S&P 500 ETF (SPY)
Smith & Nephew Snats Business Overview & Revenue Model
Smith & Nephew Snats Key Performance Indicators (KPIs)
Analyzes revenue contributions from different business units, indicating which segments are leading growth and how diversified the company's income streams are.
The FlySmith & Nephew Snats Earnings Call Summary
Smith & Nephew Snats Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.97B | 5.81B | 5.55B | 5.21B | 5.21B | 4.56B |
| Gross Profit | 4.18B | 4.05B | 3.82B | 3.67B | 3.67B | 3.16B |
| EBITDA | 1.44B | 1.24B | 956.00M | 874.00M | 1.24B | 866.00M |
| Net Income | 493.64M | 412.00M | 263.00M | 223.00M | 524.00M | 448.00M |
Balance Sheet | ||||||
| Total Assets | 10.68B | 10.35B | 9.99B | 9.97B | 10.92B | 11.01B |
| Cash, Cash Equivalents and Short-Term Investments | 675.41M | 619.00M | 302.00M | 350.00M | 1.29B | 1.76B |
| Total Debt | 3.45B | 3.32B | 3.08B | 2.87B | 3.34B | 3.69B |
| Total Liabilities | 5.15B | 5.09B | 4.77B | 4.71B | 5.35B | 5.73B |
| Stockholders Equity | 5.53B | 5.26B | 5.22B | 5.26B | 5.57B | 5.28B |
Cash Flow | ||||||
| Free Cash Flow | 799.32M | 606.00M | 181.00M | 110.00M | 469.00M | 492.00M |
| Operating Cash Flow | 1.15B | 987.00M | 608.00M | 468.00M | 877.00M | 935.00M |
| Investing Cash Flow | -345.22M | -569.00M | -448.00M | -472.00M | -691.00M | -606.00M |
| Financing Cash Flow | -676.96M | -86.00M | -200.00M | -926.00M | -645.00M | 1.16B |
Smith & Nephew Snats Technical Analysis
Smith & Nephew Snats Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $125.28B | 26.40 | 9.81% | 2.76% | 5.34% | 13.15% | |
79 Outperform | $137.79B | 50.53 | 12.66% | ― | 21.62% | 54.80% | |
79 Outperform | $49.51B | 36.12 | 13.59% | ― | 0.19% | 65.58% | |
73 Outperform | $18.02B | 22.50 | 6.41% | 1.05% | 5.47% | -23.03% | |
70 Outperform | $134.49B | 46.18 | 14.04% | 0.95% | 10.95% | -18.32% | |
69 Neutral | $13.68B | 28.58 | 9.20% | 2.31% | 5.78% | 61.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Smith & Nephew Snats Corporate Events
On December 8, 2025, Smith+Nephew announced its new RISE strategy and financial targets for 2028 at its Capital Markets Day in London. The strategy aims to elevate financial and operational performance, focusing on reaching more patients, innovating product offerings, scaling operations, and executing efficiently. The company updated its 2025 full-year guidance, expecting a trading profit margin of at least 19.5% and free cash flow around $800 million. Smith+Nephew also plans to rationalize its product portfolio, estimating a $200 million non-cash inventory provision in 2025 to simplify offerings and improve capital efficiency. The RISE strategy is expected to deliver significant shareholder value and solidify Smith+Nephew’s leadership in healthcare innovation.
Smith & Nephew Snats, a company listed on the London Stock Exchange, announced that as of November 30, 2025, its total issued share capital consists of 877,724,845 ordinary shares, with 28,000,826 held in treasury. This results in 849,724,019 ordinary shares with voting rights, which shareholders should use as the denominator for determining their interests according to the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc announced on November 19, 2025, that key executives participated in the company’s Employee Stock Purchase Plan, acquiring American Depositary Shares through the Dividend Re-Investment Plan after the interim dividend payment on November 7, 2025. This transaction, conducted on the New York Stock Exchange, underscores the company’s commitment to aligning managerial interests with shareholder value, potentially enhancing stakeholder confidence.
Smith & Nephew plc, a UK-based company, reported a change in major holdings due to an acquisition or disposal of voting rights by BlackRock, Inc. On November 14, 2025, BlackRock’s voting rights in Smith & Nephew reached a total of 7.17%, with 5.01% attached to shares and 2.16% through financial instruments. This change was officially notified on November 17, 2025.
On November 11, 2025, Smith & Nephew plc announced the vesting of 3,016 restricted shares awarded to CEO Deepak Nath under an agreement from April 2022. A portion of these shares was sold to meet tax obligations, reflecting the company’s adherence to regulatory requirements and impacting its financial disclosures. This transaction, conducted on the London Stock Exchange, underscores the company’s commitment to transparent governance and may influence stakeholder perceptions regarding executive compensation practices.
On November 10, 2025, Smith & Nephew plc, a UK-based company, reported a change in major holdings due to an acquisition or disposal of voting rights by BlackRock, Inc. The notification revealed that BlackRock’s voting rights in Smith & Nephew decreased slightly from 7.18% to 7.17%, with a total of 60,996,414 voting rights held. This adjustment in holdings reflects a minor shift in BlackRock’s investment position, which could have implications for the company’s influence over Smith & Nephew’s strategic decisions.
On November 7, 2025, Smith & Nephew plc announced the purchase of ordinary shares through its Dividend Re-Investment Plan following the interim dividend payment. This transaction, disclosed under the UK Market Abuse Regulation, involved key executives, including the CEO and presidents of various divisions, purchasing shares at a price of £12.4048 each. This move reflects the company’s commitment to aligning managerial interests with shareholder value, potentially impacting its market position positively.
On November 6, 2025, Smith & Nephew plc announced a significant transaction involving the purchase of American Depositary Shares (ADS) by Ajay Dhankhar, the Chief Corporate Strategy & Development Officer, on the New York Stock Exchange. This transaction, disclosed under the UK Market Abuse Regulation, highlights the company’s ongoing strategic activities and could indicate confidence in the company’s future performance, potentially impacting its market positioning and stakeholder interests.
Smith & Nephew plc, a company operating in the medical technology industry, announced a transaction involving the purchase of American Depositary Shares (ADS) by KAGAMA Family Investments, LP, which is closely associated with Garheng Kong, an Independent Non-Executive Director. The transaction, which took place on November 6, 2025, at the New York Stock Exchange, involved the purchase of 3,000 ADS at a price of $33.9773 each. This notification is made in compliance with the UK Market Abuse Regulation, reflecting the company’s commitment to transparency in its financial dealings.
Smith+Nephew has announced the appointment of Thérèse Esperdy as an independent Non-Executive Director and Senior Independent Director designate, effective December 1, 2025. Esperdy, who brings extensive experience from her roles in financial services and as a board member of international businesses, will succeed Angie Risley following the company’s AGM in May 2026. This strategic appointment is expected to enhance the company’s governance and strengthen its board with Esperdy’s expertise, particularly in highly regulated industries.
Smith & Nephew reported a 5.0% underlying revenue growth in the third quarter of 2025, with total revenue reaching $1,501 million. The company highlighted strong performance in its orthopaedics, sports medicine, and advanced wound management divisions, driven by new product launches and strategic initiatives. The company maintained its full-year revenue and profit margin outlook while raising its free cash flow guidance to $750 million, reflecting improved operational efficiency. A $500 million share buyback was completed, showcasing robust cash generation. Smith & Nephew’s strategic focus on innovation and product launches continues to bolster its market position and drive growth.
Smith & Nephew reported a 5.0% underlying revenue growth in the third quarter of 2025, with a total revenue of $1,501 million, driven by strong performance in orthopaedics, sports medicine, and advanced wound management. The company has completed a $500 million share buyback and raised its free cash flow guidance to $750 million, reflecting robust cash generation and operational efficiency. New product launches, such as the CORIOGRAPH Pre-Op Planning and Modeling Services and the CENTRIO PRP System, have contributed significantly to revenue growth, supporting the company’s strategic goals and enhancing its market position.
On October 31, 2025, Smith & Nephew plc reported its total issued share capital, comprising 877,724,845 ordinary shares, with 29,017,524 held in treasury. This results in 848,707,321 shares with voting rights, a crucial figure for shareholders under the FCA’s Disclosure Guidance and Transparency Rules. This announcement ensures transparency and aids stakeholders in understanding their voting power and obligations.
On October 22, 2025, BlackRock, Inc. crossed a significant threshold in its voting rights in Smith & Nephew, reaching a total of 7.18%. This change in holdings, notified on October 23, 2025, reflects a slight increase from their previous position and could impact Smith & Nephew’s shareholder dynamics and influence within the company.
Smith & Nephew plc, a global medical technology company, announced that an interim dividend of 15.0 US cents per ordinary share will be paid on November 7, 2025. Shareholders in the UK or those who opted for sterling dividends will receive 11.26 pence per share. This announcement, initially made on August 5, 2025, reflects the company’s ongoing commitment to returning value to its shareholders.
On October 16, 2025, Smith & Nephew plc released its six-monthly block listing return, detailing the status of various share schemes from February 1 to July 31, 2025. The report highlights that the Global Share Plan 2010 saw 206 securities issued, leaving 3,756 unallotted, while the Global Share Plan 2020 issued 5,758 securities, with 403,258 remaining unallotted. Other schemes, such as the Smith & Nephew ShareSave Plan and International ShareSave Plan, reported no new issuances, maintaining their previous balances. This update provides stakeholders with insights into the company’s equity distribution and potential future financial strategies.
On October 13, 2025, BlackRock, Inc., a major shareholder, adjusted its voting rights in Smith & Nephew plc, resulting in a new total of 7.17% of voting rights. This change, notified on October 14, 2025, reflects a slight increase from the previous total of 6.76%, indicating a strategic adjustment in BlackRock’s investment in the company. The adjustment in voting rights could influence Smith & Nephew’s governance and strategic decisions, impacting its market positioning and stakeholder interests.
Smith+Nephew announced it will host Capital Markets Days in London and New York on December 8 and 11, 2025, respectively. These events will introduce the company’s new strategy following its 12-Point Plan and provide insights into its innovative portfolio aimed at driving future growth. Led by CEO Deepak Nath, these sessions are significant for institutional investors and analysts, offering a detailed view of the company’s strategic direction and growth potential.
Smith & Nephew plc, a company listed on the London Stock Exchange, announced its total issued share capital as of September 30, 2025. The company reported that it has 877,724,845 ordinary shares, with 24,102,908 held in treasury, resulting in 853,621,937 shares with voting rights. This information is crucial for shareholders to determine their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules.
Smith+Nephew announced that its Chief Financial Officer, John Rogers, will relocate to the United States effective September 29, 2025, to enhance leadership and oversight in the region, which contributes significantly to the company’s revenue. This move aligns with the company’s strategy to focus on the US market, allowing closer collaboration with senior leaders and supporting the execution of business strategies. Rogers’ remuneration will be adjusted to align with US market practices, with changes to his base salary, pension cash allowance, and performance-related awards.
On September 8, 2025, Smith & Nephew plc reported the sale of ordinary shares by Alison Parkes, the Chief Compliance Officer, on the London Stock Exchange. This transaction, disclosed in accordance with the UK Market Abuse Regulation, highlights the company’s commitment to transparency in its financial dealings, potentially impacting investor perceptions and market positioning.
On September 9, 2025, Smith & Nephew announced a transaction involving the sale of ordinary shares by Vasant Padmanabhan, President of Research & Development ENT, who is classified as a Person Discharging Managerial Responsibilities (PDMR). The transaction, conducted outside the trading venue, involved the sale of 17,643 shares at a price of £14.25 each. This announcement is made in compliance with the UK Market Abuse Regulation, highlighting the company’s commitment to transparency in its financial dealings.